Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study

Experimental Gerontology
Nare TorosyanDaniel H Silverman

Abstract

Caprylidene is a ketogen that, when metabolized, produces the ketones beta-hydroxybutyrate and acetoacetate, which can cross the blood brain barrier. It has been hypothesized that ketone bodies can be used as an alternate energy source by neurons with impaired glucose utilization. Caprylidene has been shown to improve cognition in patients with mild-to-moderate Alzheimer's disease (AD) who lacked an AD-predisposing allele (ɛ4) of the gene for apolipoprotein E. In this pilot study, we examined the effects of caprylidene on regional cerebral blood flow (rCBF) in patients with mild to moderate AD. Sixteen subjects with mild-to-moderate AD, based on NINCDS-ADRDA criteria, were enrolled in a double-blinded, placebo-controlled, randomized clinical trial. Fourteen subjects received treatment with caprylidene, and 2 subjects were given placebo. Subjects received 4 15O-water PET scans over the course of the study to assess rCBF: once before receiving a standard caprylidene or placebo dose and 90 min after the dose, on the first day and after 45 days of daily caprylidene or placebo consumption. The scans were examined by standardized volumes of interest (sVOI) and voxel-based statistical parametric mapping (spm) methods of analysis. Subj...Continue Reading

Citations

Sep 11, 2019·Current Opinion in Clinical Nutrition and Metabolic Care·Tanya J W McDonald, Mackenzie C Cervenka
Apr 30, 2019·Current Opinion in Clinical Nutrition and Metabolic Care·Danielle M deCampo, Eric H Kossoff
Aug 14, 2019·International Journal of Molecular Sciences·Marta RusekStanisław J Czuczwar
Oct 20, 2019·Nutrients·Raffaella LongoMaurizio Crestani
Feb 20, 2020·Military Medicine·Jennifer M GurneyDonald W Marion
Aug 8, 2020·Nordic Journal of Psychiatry·Magnus G ChristensenAnders Fink-Jensen
Apr 21, 2020·Journal of Alzheimer's Disease : JAD·Samuel T HendersonJudith Walker
Apr 16, 2020·Alzheimer's Research & Therapy·Matthieu LilamandClaire Paquet
Jul 28, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Eric D VidoniRussell H Swerdlow
Nov 26, 2020·International Journal of Molecular Sciences·Nicole Jacqueline JensenJørgen Rungby
Dec 11, 2020·International Journal of Molecular Sciences·Sofia TonioloMasud Husain
Jul 6, 2021·Aging and Disease·Dennis A Turner
Sep 29, 2021·The British Journal of Nutrition·Étienne Myette-CôtéStephen C Cunnane

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.